PCSK9s appear to be meeting less payer resistance

PCSK9s appear to be meeting less payer resistance

Source: 
Biopharma Dive
snippet: 

Major U.S. insurers appear to be opening up to a relatively new and expensive class of cholesterol-lowering drugs. They accepted nearly three-fourths of claims for the drugs in 2017, according to a new report — a marked improvement from prior years.